1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

30 Dec 2022
Admin
News Article

Clene Nanomedicine Announces Positive Results From Phase 2 Covid-19 Study Of Cnm-Znag

Clene Inc. And Its Wholly Owned Subsidiary Clene Nanomedicine Inc., A Clinical-Stage Biopharmaceutical Company Announced Topline Study Results From Its Phase 2 Investigational Trial With Cnm-Znag, An Ionic Solution Of Zinc And Silver, For The Treatment Of Non-Hospitalized Acutely Symptomatic Participants Infected With Covid-19.The Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Assessed The Efficacy And Safety Of Cnm-Znag In Covid-19 Infected Participants In Brazil. Study Participants Were Randomized 1:1:2 To Receive Daily Low Dose Cnm-Znag, High Dose Cnm-Znag, Or Placebo In Addition To Standard Supportive Care For Up To 21 Days. The Primary Endpoint Assessed The Time To Substantial Alleviation Of Covid-19 Symptoms Through 28 Days, Confirmed Over A Continuous Period = 48 Hours, In The Modified Intent-To-Treat (Mitt) Population (All Participants With Pcr Documented Sars-Cov-2 Infection, N=288). No Clinical Benefit Was Observed Versus Placebo. Cnm-Znag Was Safe And Well-Tolerated, And No Safety Signals Were Identified.Rob Etherington, Clene

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!